Alpha 2.0
Login Register
» Authors » Germaine Hanquet

Germaine Hanquet

Explore the profile of Germaine Hanquet including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 29
Citations 564
Followers 0
Related Specialties
Allergy & Immunology
Infectious Diseases
General Medicine
Top 10 Co-Authors
Marc Baay
Philippe Beutels
Joke Bilcke
Pavla Krizova
Lucia Pastore Celentano
Camelia Savulescu
Pieter Neels
Carmen Munoz-Almagro
Jolita Mereckiene
Brita A Winje
Published In
Vaccine
Emerg Infect Dis
Front Public Health
Pediatr Infect Dis J
Epidemics
Affiliations
Soon will be listed here.
Recent Articles
1.
Serotype distribution of invasive pneumococcal disease from countries of the WHO Africa, Americas, Eastern Mediterranean, South-East Asia, and Western Pacific regions: a systematic literature review from 2010 to 2021
Fletcher M, Daigle D, Siapka M, Baay M, Hanquet G, Del Carmen Morales G
Front Public Health . 2024 Jul; 12:1402795. PMID: 39050608
Background: Most publications on invasive pneumococcal disease (IPD) serotype distribution are from about 20 countries (Australia, Canada, China, European Union members, Japan, New Zealand, South Korea, and USA). Here, we...
2.
Effects of PCV10 and PCV13 on pneumococcal serotype 6C disease, carriage, and antimicrobial resistance
Grant L, Hanquet G, Sepulveda-Pachon I, Theilacker C, Baay M, Slack M, et al.
Vaccine . 2024 Mar; 42(12):2983-2993. PMID: 38553292
Background: The cross-protection of pneumococcal conjugate vaccines (PCV) against serotype 6C is not clearly documented, although 6C represents a substantial burden of pneumococcal disease in recent years. A systematic review...
3.
Best Practices for Identifying Hospitalized Lower Respiratory Tract Infections Using Administrative Data: A Systematic Literature Review of Validation Studies
Hanquet G, Theilacker C, Vietri J, Sepulveda-Pachon I, Menon S, Gessner B, et al.
Infect Dis Ther . 2024 Mar; 13(4):921-940. PMID: 38498108
Introduction: Estimating the burden of lower respiratory tract infections (LRTIs) increasingly relies on administrative databases using International Classification of Diseases (ICD) codes, but no standard methodology exists. We defined best...
4.
Effect of Pneumococcal Conjugate Vaccines on Viral Respiratory Infections: A Systematic Literature Review
Sepulveda-Pachon I, Dunne E, Hanquet G, Baay M, Menon S, Jodar L, et al.
J Infect Dis . 2024 Mar; 230(3):e657-e667. PMID: 38462672
Background: In addition to preventing pneumococcal disease, emerging evidence indicates that pneumococcal conjugate vaccines (PCVs) might indirectly reduce viral respiratory tract infections (RTIs) by affecting pneumococcal-viral interactions. Methods: We performed...
5.
Systematic Literature Review of the Epidemiological Characteristics of Pneumococcal Disease Caused by the Additional Serotypes Covered by the 20-Valent Pneumococcal Conjugate Vaccine
Meroc E, Fletcher M, Hanquet G, Slack M, Baay M, Hayford K, et al.
Microorganisms . 2023 Jul; 11(7). PMID: 37512988
Higher valency pneumococcal conjugate vaccines (PCV15 and PCV20) have been developed to address the disease burden of current non-vaccine serotypes. This review describes the epidemiological characteristics of serotypes beyond PCV13...
6.
Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study
Savulescu C, Krizova P, Valentiner-Branth P, Ladhani S, Rinta-Kokko H, Levy C, et al.
Vaccine . 2022 May; 40(29):3963-3974. PMID: 35637067
Background: Pneumococcal conjugate vaccines covering 10 (PCV10) and 13 (PCV13) serotypes have been introduced in the infant immunization schedule of most European countries in 2010-11. To provide additional real-life data,...
7.
Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
Hanquet G, Krizova P, Dalby T, Ladhani S, Nuorti J, Danis K, et al.
Emerg Infect Dis . 2021 Dec; 28(1):137-138. PMID: 34932457
We evaluated invasive pneumococcal disease (IPD) during 8 years of infant pneumococcal conjugate vaccine (PCV) programs using 10-valent (PCV10) and 13-valent (PCV13) vaccines in 10 countries in Europe. IPD incidence...
8.
Vaccine-Preventable Disease Incidence Based on Clinically, Radiologically, and Etiologically Confirmed Outcomes: Systematic Literature Review and Re-analysis of Pneumococcal Conjugate Vaccine Efficacy Trials
Bollaerts K, Fletcher M, Suaya J, Hanquet G, Baay M, Gessner B
Clin Infect Dis . 2021 Jul; 74(8):1362-1371. PMID: 34313721
Background: Vaccine regulatory decision making is based on vaccine efficacy against etiologically confirmed outcomes, which may underestimate the preventable disease burden. To quantify this underestimation, we compared vaccine-preventable disease incidence...
9.
Meeting report narcolepsy and pandemic influenza vaccination: What we know and what we need to know before the next pandemic? A report from the 2nd IABS meeting
Edwards K, Hanquet G, Black S, Mignot E, Jankosky C, Shimabukuro T, et al.
Biologicals . 2019 May; 60:1-7. PMID: 31130313
A group of scientific and public health experts and key stakeholders convened to discuss the state of knowledge on the relationship between adjuvanted monovalent inactivated 2009 influenza A H1N1 vaccines...
10.
Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination
Hanquet G, Krizova P, Valentiner-Branth P, Ladhani S, Nuorti J, Lepoutre A, et al.
Thorax . 2018 Oct; 74(5):473-482. PMID: 30355641
Background: Pneumococcal conjugate vaccines (PCVs) have the potential to prevent pneumococcal disease through direct and indirect protection. This multicentre European study estimated the indirect effects of 5-year childhood PCV10 and/or...